Showing BioInteractions for ATP (DB00171)
BioInteractor utilizes data on drug-target, -enzyme and -transporter associations to provide insight on drug-drug interactions. It allows you to identify, for instance, which drugs act similarly on the same target. Such drugs may have additive pharmacodynamic effects if given concomitantly. Conversely, two drugs may antagonize the beneficial effects of each other by having opposite actions on a specific drug target. BioInteractor uses ranked drug-enzyme association information to predict enzyme-mediated drug interactions that may be clinically relevant.
Interacting Group | Interacting Drugs | |
---|---|---|
ATP is a Tyrosine-protein kinase ABL2 inhibitor | ||
1 | Tyrosine-protein kinase ABL2 inhibitors | Fostamatinib |
Interacting Group | Interacting Drugs | |
---|---|---|
ATP is a Tyrosine-protein kinase ABL1 inhibitor | ||
1 | Tyrosine-protein kinase ABL1 inhibitors | Bosutinib, Brigatinib, Fostamatinib, Imatinib, Nilotinib, Ponatinib, Regorafenib, Umbralisib |
2 | Tyrosine-protein kinase ABL1 antagonists | Radotinib |
3 | Tyrosine-protein kinase ABL1 substrates | Magnesium gluconate |
4 | Tyrosine-protein kinase ABL1 inducers | Magnesium gluconate |
Interacting Group | Interacting Drugs | |
---|---|---|
ATP is a Cystic fibrosis transmembrane conductance regulator cofactor | ||
1 | Cystic fibrosis transmembrane conductance regulator antagonists | Bumetanide, Crofelemer, Glyburide |
2 | Cystic fibrosis transmembrane conductance regulator potentiators | Ivacaftor |
3 | Cystic fibrosis transmembrane conductance regulator inhibitors | Colforsin, Dexibuprofen, Ibuprofen |
4 | Cystic fibrosis transmembrane conductance regulator modulators | Elexacaftor, Lumacaftor |
5 | Cystic fibrosis transmembrane conductance regulator activators | Tezacaftor |
Interacting Group | Interacting Drugs | |
---|---|---|
ATP is a Adenosine kinase substrate | ||
1 | Adenosine kinase substrates | Abacavir, Adenosine |
2 | Adenosine kinase activators | Ribavirin |